Neuroscientific Biopharmaceuticals Ltd has released a press release.
Completion of Safety Pharmacology Studies
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuroscientific Biopharmaceuticals Ltd. on 6ix
Earlier from Neuroscientific Biopharmaceuticals
- NSB Receives R&D Advance & Overseas Finding
- Positive Results in Multiple Sclerosis Study
- 2021 Annual Report and Appendix 4E
- Results from Pulmonary Studies Clarification
- Pause in Trading
Later from Neuroscientific Biopharmaceuticals
- Positive results in biomarker characterisation of Emtins
- Positive off-target safety assessment of EmtinB
- Successful completion of key studies in lead up to Phase I
- NSB 1HY22 Key Activity Highlights
- New data demonstrates EmtinB activity in autoimmune diseases
Follow Neuroscientific Biopharmaceuticals into a list and get an email when it puts out news.
Follow Neuroscientific Biopharmaceuticals